Reinsurance Group of America, Incorporated is an insurance holding company formed on December 31, 1992, that provides traditional life and health reinsurance and asset-intensive financial solutions. The company operates through geographic segments in the U.S., Latin America, Canada, Europe, the Middle East, Africa, Asia, and Australia. Its traditional reinsurance business includes individual and group life, health, disability, long-term care, and critical illness reinsurance, written on a facultative or automatic treaty basis. Financial solutions encompass asset-intensive reinsurance, longevity reinsurance, stable value products, pension risk transfer transactions, and capital solutions. The company serves insurance companies seeking to manage investment risk, stabilize operating results, and meet regulatory requirements. RGA partners with clients to provide customized arrangements for pension plan sponsors and annuity providers, assuming longevity and investment risks. The company is the only global reinsurance provider focusing primarily on life- and health-related reinsurance solutions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Insurance - Reinsurance Homepage rgare.com
Sector Financial Services IR page investor.rgare.com
Tags
life reinsurance, health reinsurance, longevity reinsurance, pension risk transfer, asset-intensive reinsurance, stable value products, disability reinsurance, critical illness reinsurance, long-term care reinsurance, capital solutions
Press page rgare.com/our-company/media/press-releases/press-releases-detail

Metrics

Valuation  
Market cap $ 17.663B
Market cap (USD) $ 17.663B
P/E 10.52
PEG 0.44
P/BV 1.52
P/S 0.65
P/OCF 6.75
P/FCF 4.32
Dividend yield 1.4%
Turnover / mcap —
Returns  
ROE 9.7%
ROI 6.2%
ROIC 6.2%
Profit margin 5.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 23.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 25
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 23.698B 22.107B 18.567B 16.258B 16.658B 14.596B 14.3B 12.876B 12.516B 11.522B 10.418B 10.904B 10.318B 9.841B 8.83B 8.262B 7.067B 5.681B 5.718B 5.194B 4.585B 4.039B 3.174B 2.382B 1.968B 1.726B
Net profit 1.182B 717M 902M 623M 617M 415M 870M 715.842M 1.822B 701.443M 502.166M 684.047M 418.837M 631.893M 599.62M 574.402M 407.086M 176.796M 293.834M 288.21M 224.18M 221.891M 173.141M 122.806M 33.046M 77.669M
Free cash flow 4.091B 9.37B 4.044B 1.318B 4.163B 3.294B 2.273B 1.552B 1.938B 1.421B 2.065B 2.248B — — — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 203.46 213.63 161.78 142.09 109.49 115.9 163.06 140.23 155.93 125.83 85.55 87.62 77.41 53.52 52.24 49.81 47.88 36.72 63.04 55.18 — — — — — —
Price performance 12m -0.05 0.32 0.14 0.3 -0.06 -0.29 0.16 -0.1 0.24 0.47 -0.02 0.13 0.45 0.02 0.05 0.04 0.3 -0.42 0.14 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 1.2B 1.3B 1.89B 1.45B 3.41B 2.95B 2.93B 2.97B 3.33B 4.17B
Cash flow detail
Operating cash flow (USD) 1.47B 1.98B 1.58B 2.31B 3.32B 4.18B 1.34B 4.04B 9.37B 4.09B
Purchases of property, plant and equipment (USD) -44.6M -44.2M -28.9M -34M -28M -19M -25M — — —
Dividends paid (cash effect) (USD) -100M -117M -140M -163M -182M -194M -205M -219M -229M -240M
Interest paid (cash effect) (USD) -157M -173M -170M -180M -166M -160M -163M -217M -213M -255M
Income taxes paid (cash effect) (USD) -61.1M -37.1M -142M -44M -108M -368M -129M -298M -78M -252M
Share-based compensation (USD) 33.1M 22.3M 30.1M 39M -12M 55M 45M 46M 60M 42M
Free cash flow (OCF - PPE - intangibles) (USD) 1.42B 1.94B 1.55B 2.27B 3.29B 4.16B 1.32B — — —
Income detail
Total comprehensive income (USD) 1.13B 2.59B -708M 3.37B 2.64B -1.1B -8.62B 2.41B 1.94B 3.02B
Comprehensive income to owners (USD) 1.13B 2.59B -708M 3.37B 2.64B -1.1B -8.62B 2.4B 1.94B 3.02B
Reported Feb 28, 2017 Feb 27, 2018 Feb 27, 2019 Feb 27, 2020 Feb 26, 2021 Feb 25, 2022 Feb 24, 2023 Feb 26, 2024 Feb 21, 2025 Feb 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

Third Quarter Results

  • Net income available to RGA shareholders of $6.92 per diluted share, compared with $3.81 per diluted share in the prior-year quarter.

  • Adjusted operating income of $8.49 per diluted share, compared with $4.66 per diluted share in the prior-year quarter.

  • Return on equity (“ROE”) of 13.1%; adjusted operating ROE of 19.2%; adjusted operating ROE, excluding notable items, of 19.1%, each for the trailing twelve months.

  • Returned $139 million to shareholders in the quarter, including $75 million in share repurchases and $64 million in dividends paid.

ST. LOUIS--(BUSINESS WIRE)--Nov. 5, 2026-- Reinsurance Group of America, Incorporated (NYSE: RGA), a leading global provider of life and health reinsurance, reported third quarter net income available to RGA shareholders of $456 million, or $6.92 per diluted share, compared with $253 million, or $3.81 per diluted share, in the prior-year quarter. Adjusted operating income for the third quarter totaled $558 million, or $8.49 per diluted share, compared with $310 million, or $4.66 per diluted share, in the prior-year quarter. Adjusted operating income, excluding notable items, for the third quarter totaled $558 million, or $8.49 per diluted share, compared with $424 million, or $6.37 per diluted share, in the prior-year quarter. Net foreign currency fluctuations had an unfavorable effect of $0.11 per diluted share on net income available to RGA shareholders and $0.15 per diluted share on adjusted operating income, both compared with the prior-year quarter.

Tony Cheng, President and Chief Executive Officer, commented, “RGA delivered excellent results this quarter with strong performance across all regions. Investment performance was robust, and claims experience was favorable to expectations, demonstrating continued strong fundamentals underpinned by a long history of biometric expertise and superior investment capabilities.

“These results reinforce the strategic advantages of RGA’s diversified platform and our ability to generate attractive, risk-adjusted returns across a range of market environments. We continued to maintain our disciplined approach to capital deployment with a focus on high return, quality business as well as shareholder returns. Our pipeline for both in-force and flow business remains healthy and supports our confidence in RGA continuing to deliver strong financial results for the remainder of 2026 and beyond.”

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions, except per share data) | 2026 | | 2025 | | 2026 | | 2025 |

| Net premiums | $ | 5,352 | | $ | 4,280 | | $ | 14,419 | | $ | 12,450 |

| Net income available to RGA shareholders | | 456 | | | 253 | | | 1,248 | | | 719 |

| Net income available to RGA shareholders per diluted share | | 6.92 | | | 3.81 | | | 18.91 | | | 10.78 |

| Adjusted operating income | | 558 | | | 310 | | | 1,606 | | | 1,003 |

| Adjusted operating income, excluding notable items | | 558 | | | 424 | | | 1,606 | | | 1,117 |

| Adjusted operating income per diluted share | | 8.49 | | | 4.66 | | | 24.34 | | | 15.04 |

| Adjusted operating income, excluding notable items per diluted share | | 8.49 | | | 6.37 | | | 24.34 | | | 16.75 |

| Book value per share | | 178.89 | | | 197.52 | | | 178.89 | | | 197.52 |

| Book value per share, excluding accumulated other comprehensive income (AOCI) | | 179.51 | | | 158.67 | | | 179.51 | | | 158.67 |

| Book value per share, excluding AOCI and B36 | | 178.59 | | | 159.83 | | | 178.59 | | | 159.83 |

| Total assets | | 169,520 | | | 152,003 | | | | |

Information regarding the non-GAAP financial measures and operating measures included in this press release, including definitions of these measures, reconciliations to the most comparable GAAP measures and limitations related thereto, is included below under “Non-GAAP Financial Measures and Other Definitions” and in the tables attached to this press release.

RGA completed its annual actuarial assumption review. There was no net impact to consolidated pre-tax adjusted operating income as a result of this review.

In the third quarter, consolidated net premiums totaled $5.4 billion, an increase of 25.0% compared with the prior-year quarter, with an adverse net foreign currency effect of $16 million. Net premiums for the quarter included approximately $800 million from single premium pension risk transfer transactions, which are included in the U.S. Financial Solutions business, compared with no contribution from these transactions in the prior-year quarter.

Investment income for the quarter, excluding spread-based businesses, increased 17.5% compared with the prior-year quarter, primarily due to a larger average invested asset base, higher variable income and accretive new money rates. Average investment yield was 5.26% in the quarter compared with 4.73% in the prior-year quarter, reflecting higher variable investment income and accretive new money rates.

The effective tax rate for the quarter was 26.8% on pre-tax income, above the expected range of 22% to 23%, primarily due to the jurisdictional mix of earnings and an increase in the valuation allowance. The effective tax rate for the quarter was 24.1% on adjusted operating income before taxes, above the expected range of 22% to 23%, primarily due to the jurisdictional mix of earnings and an increase in the valuation allowance.

SEGMENT RESULTS

U.S. and Latin America

Traditional

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Net premiums | $ | 1,930 | | $ | 1,883 | | $ | 5,823 | | $ | 5,823 |

| Adjusted operating income before taxes | | 176 | | | 136 | | | 479 | | | 280 |

| Adjusted operating income before taxes, excluding notable items | | 163 | | | 97 | | | 466 | | | 241 |

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to more favorable claims experience and the continued favorable impacts of in-force actions executed in prior periods.

  • Results reflected $13 million of favorable impacts from the 2026 annual actuarial assumption review, which are reflected as notable items.

Financial Solutions

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Adjusted operating income before taxes | $ | 119 | | $ | 100 | | $ | 391 | | $ | 264 |

| Adjusted operating income before taxes, excluding notable items | | 127 | | | 100 | | | 399 | | | 264 |

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to strong variable investment income.

  • Results reflected $8 million of unfavorable impacts from the 2026 annual actuarial assumption review, which are reflected as notable items.

Canada

Traditional

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Net premiums | $ | 346 | | $ | 326 | | $ | 1,033 | | $ | 984 |

| Adjusted operating income before taxes | | 63 | | | 43 | | | 139 | | | 103 |

| Adjusted operating income before taxes, excluding notable items | | 41 | | | 34 | | | 117 | | | 94 |

Net Premiums

  • Foreign currency exchange rates had an adverse effect on net premiums of $6 million for the quarter.

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to more favorable claims experience.

  • Results reflected $22 million of favorable impacts from the 2026 annual actuarial assumption review, which are reflected as notable items.

Financial Solutions

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Adjusted operating income before taxes | $ | 17 | | $ | 7 | | $ | 45 | | $ | 27 |

| Adjusted operating income before taxes, excluding notable items | | 17 | | | 7 | | | 45 | | | 27 |

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to strong variable investment income.

Europe, Middle East and Africa (EMEA)

Traditional

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Net premiums | $ | 556 | | $ | 562 | | | $ | 1,729 | | $ | 1,675 | |

| Adjusted operating income before taxes | | 21 | | | (192 | ) | | | 114 | | | (124 | ) |

| Adjusted operating income before taxes, excluding notable items | | 52 | | | 30 | | | | 145 | | | 98 | |

Net Premiums

  • Foreign currency exchange rates had a positive effect of $3 million on net premiums for the quarter.

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to more favorable claims experience.

  • Results reflected $31 million of unfavorable impacts from the 2026 annual actuarial assumption review, which are reflected as notable items.

  • Foreign currency exchange rates had an adverse effect of $4 million on adjusted operating income before taxes for the quarter.

Financial Solutions

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Adjusted operating income before taxes | $ | 151 | | $ | 140 | | $ | 412 | | $ | 346 |

| Adjusted operating income before taxes, excluding notable items | | 151 | | | 116 | | | 412 | | | 322 |

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to contributions of new business including the associated higher investment income.

Asia Pacific

Traditional

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Net premiums | $ | 863 | | $ | 880 | | $ | 2,573 | | $ | 2,473 |

| Adjusted operating income before taxes | | 119 | | | 138 | | | 373 | | | 348 |

| Adjusted operating income before taxes, excluding notable items | | 111 | | | 137 | | | 365 | | | 347 |

Net Premiums

  • Foreign currency exchange rates had an adverse effect on net premiums of $3 million for the quarter.

Quarterly Results

  • Results excluding notable items decreased compared to the prior-year quarter, primarily due to less favorable claims experience.

  • Results reflected $8 million of favorable impacts from the 2026 annual actuarial assumption review, which are reflected as notable items.

  • Foreign currency exchange rates had an adverse effect of $6 million on adjusted operating income before taxes for the quarter.

Financial Solutions

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | 2026 | | 2025 | | 2026 | | 2025 |

| Adjusted operating income before taxes | $ | 92 | | $ | 71 | | $ | 277 | | $ | 207 |

| Adjusted operating income before taxes, excluding notable items | | 96 | | | 71 | | | 281 | | | 207 |

Quarterly Results

  • Results excluding notable items increased compared to the prior-year quarter, primarily due to new business growth and strong variable investment income.

  • Results reflected $4 million of unfavorable impacts from the 2026 annual actuarial assumption review, which are reflected as notable items.

  • Foreign currency exchange rates had an adverse effect of $3 million on adjusted operating income before taxes for the quarter.

Corporate and Other

| | Quarterly Results | | Year-to-Date Results |

| ($ in millions) | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Adjusted operating income (loss) before taxes | $ | (22 | ) | | $ | (58 | ) | | $ | (122 | ) | | $ | (160 | ) |

| Adjusted operating income (loss) before taxes, excluding notable items | | (22 | ) | | | (58 | ) | | | (122 | ) | | | (160 | ) |

Quarterly Results

  • Results increased compared to the prior-year quarter due to strong variable investment income.

Dividend Declaration

Effective October 22, 2026, the Board of Directors declared a regular quarterly dividend of $0.98, payable December 1, 2026, to shareholders of record as of November 17, 2026.

Earnings Conference Call

A conference call to discuss third quarter results will begin at 10 a.m. Eastern Time on Friday, November 6, 2026. Interested parties may access the call by dialing 1-844-481-2753 (1-412-317-0669 international) and asking to be joined into the Reinsurance Group of America, Incorporated (RGA) call. A live audio webcast of the conference call will be available on RGA’s Investor Relations website at www.rgare.com. A replay of the conference call will be available at the same website for 90 days following the conference call.

RGA has posted to its website an earnings presentation and a Quarterly Financial Supplement that includes financial information for all segments as well as information on its investment portfolio. Additionally, RGA posts periodic reports, press releases and other useful information on its Investor Relations website.

Non-GAAP Financial Measures and Other Definitions

Reinsurance Group of America, Incorporated (the “Company”) discloses certain financial measures that are not determined in accordance with U.S. GAAP. The Company principally uses such non-GAAP financial measures in evaluating performance because the Company believes that such measures, when reviewed in conjunction with relevant U.S. GAAP measures, present a clearer picture of the Company’s operating performance and assist the Company in the allocation of its resources. The Company believes that these non-GAAP financial measures provide investors and other third parties with a better understanding of the Company’s results of operations, financial statements and the underlying profitability drivers and trends of the Company’s businesses by excluding specified items which may not be indicative of the Company’s ongoing operating performance and may fluctuate significantly from period to period. These measures should be considered supplementary to the Company’s financial results that are presented in accordance with U.S. GAAP and should not be viewed as a substitute for U.S. GAAP measures. Other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way the Company calculates such measures. Consequently, the Company’s non-GAAP financial measures may not be comparable to similar measures used by other companies.

The following non-GAAP financial measures are used in this document or in other public disclosures made by the Company from time to time:

| 1. | Adjusted operating income, on a pre-tax and after-tax basis, and adjusted operating income per diluted share. The Company uses these measures as a basis for analyzing financial results because the Company believes that such measures better reflect the ongoing profitability and underlying trends of the Company’s continuing operations. Adjusted operating income is calculated as net income available to the Company’s shareholders (or, in the case of pre-tax adjusted operating income, income before income taxes) excluding, as applicable: |

| | * substantially all of the effect of net investment related gains and losses; * changes in the fair value of embedded derivatives; * changes in the fair value of contracts that provide market risk benefits; * the Company’s non-economic losses at contract inception for direct pension risk transfer single premium business (which are amortized into adjusted operating income within adjusted claims and other policy benefits over the estimated lives of the contracts); * any net gain or loss from discontinued operations; * the cumulative effect of any accounting changes; * the impact of certain tax-related items; and * any other items that the Company believes are not indicative of the Company’s ongoing operations; |

| | |

| | as any of the above items can be volatile and may not reflect the underlying performance of the Company’s businesses. In addition, adjusted operating income per diluted share is calculated as adjusted operating income divided by weighted average diluted shares outstanding. These measures also serve as a basis for establishing target levels and awards under the Company’s management incentive programs. |

| | |

| Adjusted operating income (loss) before income taxes, when presented at a segment level, is a measure reported to our management for purposes of making decisions about allocating resources to our business segments and assessing the performance of our business segments, and is presented in our financial statement footnotes in our periodic reports in accordance with ASC 280 – “Segment Reporting.” Adjusted operating income (loss) before income taxes, when presented on a consolidated basis, is a non-GAAP financial measure. |

| | |

| 2. | **Adjusted operating income (on a pre-tax and after-tax basis), excluding notable items, and adjusted operating income per diluted share, excluding notable items.**Notable items are items that the Company believes may not be indicative of its ongoing operating performance which are excluded from adjusted operating income to provide investors and other third parties with a better understanding of the Company’s results. Such items may be unexpected, unknown when the Company prepares its business plan or otherwise. Notable items presented include the financial impact of the Company’s assumption reviews. |

| | |

| 3. | Adjusted operating revenue. This measure excludes the effects of net realized capital gains and losses, and changes in the fair value of certain embedded derivatives. |

| | |

| 4. | **Shareholders’ equity position excluding the impact of accumulated other comprehensive income (loss) (“AOCI”), shareholders’ average equity position excluding AOCI, and book value per share excluding the impact of AOCI.**The Company believes that these measures provide useful information since such measures exclude AOCI-related items that are not permanent and can fluctuate significantly from period to period, and may not reflect the impact of the underlying performance of the Company’s businesses on shareholders’ equity and book value per share. AOCI primarily relates to changes in interest rates, credit spreads on the Company’s investment securities, future policy benefits discount rate measurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and foreign currency fluctuations. The Company also discloses the following non-GAAP financial measures: |

| | * Shareholders’ average equity position excluding AOCI and B36, where B36 refers to the cumulative change in fair value of funds withheld embedded derivatives; * Shareholders’ average equity position excluding AOCI and notable items; * Shareholders’ average equity position excluding AOCI, B36 and notable items; and * Book value per share, excluding AOCI and B36. |

| 5. | **Adjusted operating return on equity, and adjusted operating return on equity, excluding notable items.**Adjusted operating return on equity is calculated as adjusted operating income divided by average shareholders’ equity excluding AOCI, and adjusted operating return on equity, excluding notable items, is calculated as adjusted operating income, excluding notable items, divided by average shareholders’ equity excluding AOCI. Adjusted operating return on equity also serves as a basis for establishing target levels and awards under the Company’s management incentive programs. The Company also discloses the following non-GAAP financial measures: |

| | * Adjusted operating return on equity excluding AOCI and B36; * Adjusted operating return on equity excluding AOCI and notable items, which is calculated as adjusted operating income excluding notable items divided by average shareholders’ equity excluding notable items and AOCI; and * Adjusted operating return on equity excluding AOCI, B36 and notable items. |

Reconciliations of the foregoing non-GAAP financial measures (to the extent disclosed in this document) to the most comparable GAAP financial measures are provided in the Appendix at the end of this document. Except as otherwise noted herein, the non-GAAP figures and reconciliations presented herein reflect the Company’s adoption of the Financial Accounting Standards Board’s Accounting Standards Update No. 2018-12, “Targeted Improvements to the Accounting for Long-Duration Contracts” and related amendments (“LDTI”). For additional information regarding the Company’s adoption of LDTI, see Note 1 – “Business and Basis of Presentation” and Note 3 – “Impact of New Accounting Standard” in the notes to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

The Company is unable to provide reconciliations of the intermediate term targets of consolidated adjusted operating income (loss) before taxes, adjusted operating income (loss) before taxes, excluding notable items (on both a segment-level and consolidated basis), consolidated adjusted operating ROE, respectively, which are forward-looking non-GAAP financial measures, due to, among other things, the fact that these targets are a composite of our goals for future results, the inherent difficulty in forecasting generally, and the difficulty of quantifying accurate forecasts of the numerous components comprising these calculations that would be necessary to provide any such reconciliations. In addition, actual performance in future periods may vary from the intermediate term target ranges for a variety of reasons, including known and unknown risk and uncertainties.

Other Definitions:

Uncapped (profitable) cohorts: Cohorts with a net premium ratio under 100%.

Capped (loss) cohorts: Cohorts with a net premium ratio equal to or greater than 100%.

Floored cohorts: Cohorts with reserves floored at zero as reserves cannot be negative.

About RGA

Reinsurance Group of America, Incorporated (NYSE: RGA) is a global industry leader specializing in life and health reinsurance and financial solutions that help clients effectively manage risk and optimize capital. Founded in 1973, RGA is one of the world’s largest and most respected reinsurers and remains guided by a powerful purpose: to make financial protection accessible to all. As a global capabilities and solutions leader, RGA empowers partners through bold innovation, relentless execution, and dedicated client focus – all directed toward creating sustainable long-term value. RGA has approximately $4.4 trillion of life reinsurance in force and total assets of $169.5 billion as of September 30, 2026. To learn more about RGA and its businesses, please visit www.rgare.com or follow RGA on LinkedIn and Facebook. Investors can learn more at investor.rgare.com.

Cautionary Note Regarding Forward-Looking Statements

This document and the documents incorporated by reference herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and federal securities laws including, among others, statements relating to projections of the future operations, strategies, earnings, revenues, income or loss, ratios, financial performance, and growth potential of Reinsurance Group of America, Incorporated (the “Company”). Forward-looking statements often contain words and phrases such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “pro forma,” “project,” “should,” “will,” “would,” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. Forward-looking statements are based on management’s current expectations and beliefs concerning future developments and their potential effects on the Company. Forward-looking statements are not a guarantee of future performance and are subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results, performance, and achievements could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Factors that could also cause results or events to differ, possibly materially, from those expressed or implied by forward-looking statements, include, among others: (1) changes in mortality, morbidity, policyholder behavior, claims experience, investment returns, interest rates, expenses and other factors as compared to our pricing assumptions; (2) investment results, whether from changes in economic, capital- and credit-market conditions, asset selection, or otherwise, and their impact on the Company’s investment securities, liquidity, portfolio yields, credit quality, access to capital, cost of capital, and amount of capital required for regulatory and contractual purposes; (3) changes in the Company’s financial strength and credit ratings and the effect of such changes on the Company; (4) the availability, amount, cost, and market value of collateral necessary for regulatory reserves, capital, and client obligations; (5) changes in laws and regulations, tax policy and rates, accounting standards, and privacy, data security and cybersecurity regulations applicable to the Company and actions by regulators with authority over the Company’s operations, as well as regulatory restrictions on the ability of Company subsidiaries to pay dividends to the Company; (6) the impact of general economic conditions in the U.S. and globally, including as a result of inflation, interest rate levels, geopolitical instability, and impacts from the imposition of, or changes in tariffs, as well as the stability of and actions by governments, central banks, and economies in jurisdictions where the Company operates, affecting interest rates, markets generally, or the demand for insurance and reinsurance; (7) the stability and financial performance of clients, reinsurers, third-party investment managers and other institutions and the effects of the Company’s dependence on such third parties; (8) the effectiveness of the Company’s risk management strategy, policy, and procedures, whether relating to reinsurance, investment strategy, operations, or otherwise; (9) the impact of impairments of the value of the Company’s investment securities on the Company’s capital requirements and the fact that the determination of allowances and impairments taken on the Company’s investments is highly subjective; (10) the threat of catastrophic events such as pandemics, epidemics, other major health issues, natural disasters, war, military actions (including conflicts in the Middle East), and terrorism or other acts of violence; (11) competitive factors and competitors’ responses to the Company’s initiatives; (12) development and introduction of new products and distribution opportunities and entry into new lines of business and markets; (13) the impact of the development and adoption of artificial intelligence; (14) the effect of acquisitions and other significant transactions, including risks related to the integration of acquired blocks of business and entities and the Company’s ability to achieve the expected benefits of such transactions, including the transaction entered into with subsidiaries of Equitable Holdings, Inc. on July 31, 2025; (15) interruption or failure of the Company’s telecommunication, information technology, or other operational systems, or the Company’s failure to maintain adequate security to protect the confidentiality or privacy of personal or sensitive data and intellectual property stored on such systems; (16) adverse developments with respect to litigation, arbitration, or regulatory investigations or actions; (17) risks associated with our international operations, including related to fluctuation in foreign currency exchange rates; and (18) other risks and uncertainties described in this document and in the Company’s other filings with the Securities and Exchange Commission (“SEC”).

Forward-looking statements should be evaluated together with the many risks and uncertainties that affect the Company’s business, including those mentioned in this document and the documents incorporated by reference herein and described in the periodic reports the Company files with the SEC. These forward-looking statements speak only as of the date on which they are made. The Company does not undertake any obligation to update these forward-looking statements, even though the Company’s situation may change in the future, except as required under applicable securities law. For a discussion of the risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements, you are advised to see Item 1A – “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as may be supplemented by Item 1A – “Risk Factors” in the Company’s subsequent Quarterly Reports on Form 10-Q and in the Company’s other periodic and current reports filed with the SEC.

| REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES Reconciliation of Consolidated Net Income to Adjusted Operating Income (Dollars in millions, except per share data) |

| | |

| (Unaudited) | Three Months Ended September 30, |

| | 2026 | | 2025 |

| | | | Diluted Earnings Per Share | | | | Diluted Earnings Per Share |

| Net income available to RGA shareholders | $ | 456 | | | $ | 6.92 | | | $ | 253 | | | $ | 3.81 | |

| Reconciliation to adjusted operating income: | | | | | | | |

| Realized (gains) losses, derivatives and other, included in investment related gains (losses), net | | 172 | | | | 2.64 | | | | (2 | ) | | | (0.05 | ) |

| Market risk benefits remeasurement (gains) losses | | (21 | ) | | | (0.32 | ) | | | — | | | | — | |

| Realized (gains) losses on funds withheld, included in investment income, net of related expenses | | (1 | ) | | | (0.02 | ) | | | 15 | | | | 0.23 | |

| Embedded derivatives: | | | | | | | |

| Included in investment related gains/losses, net | | (82 | ) | | | (1.25 | ) | | | 26 | | | | 0.39 | |

| Included in interest credited | | 4 | | | | 0.06 | | | | 1 | | | | 0.02 | |

| Investment (income) loss on unit-linked variable annuities | | — | | | | — | | | | 1 | | | | 0.02 | |

| Interest credited on unit-linked variable annuities | | — | | | | — | | | | (1 | ) | | | (0.02 | ) |

| Interest expense on uncertain tax positions | | — | | | | — | | | | — | | | | — | |

| Other (1) | | 14 | | | | 0.21 | | | | 11 | | | | 0.17 | |

| Uncertain tax positions and other tax related items | | 15 | | | | 0.23 | | | | 4 | | | | 0.06 | |

| Net income attributable to noncontrolling interest | | 1 | | | | 0.02 | | | | 2 | | | | 0.03 | |

| Adjusted operating income | | 558 | | | | 8.49 | | | | 310 | | | | 4.66 | |

| Less notable items | | — | | | | — | | | | (114 | ) | | | (1.71 | ) |

| Adjusted operating income, excluding notable items | $ | 558 | | | $ | 8.49 | | | $ | 424 | | | $ | 6.37 | |

| (1) | The Other line item includes pension risk transfer day one loss, market value adjustments on surrender charges and other immaterial items. |

| (Unaudited) | Nine Months Ended September 30, |

| | 2026 | | 2025 |

| | | | Diluted Earnings Per Share | | | | Diluted Earnings Per Share |

| Net income available to RGA shareholders | $ | 1,248 | | | $ | 18.91 | | | $ | 719 | | | $ | 10.78 | |

| Reconciliation to adjusted operating income: | | | | | | | |

| Realized (gains) losses, derivatives and other, included in investment related gains (losses), net | | 470 | | | | 7.12 | | | | 115 | | | | 1.75 | |

| Market risk benefits remeasurement (gains) losses | | (24 | ) | | | (0.36 | ) | | | 9 | | | | 0.13 | |

| Realized (gains) losses on funds withheld, included in investment income, net of related expenses | | 4 | | | | 0.06 | | | | 13 | | | | 0.19 | |

| Embedded derivatives: | | | | | | | |

| Included in investment related gains/losses, net | | (116 | ) | | | (1.76 | ) | | | 32 | | | | 0.48 | |

| Included in interest credited | | 6 | | | | 0.09 | | | | 10 | | | | 0.15 | |

| Investment (income) loss on unit-linked variable annuities | | 1 | | | | 0.02 | | | | 1 | | | | 0.01 | |

| Interest credited on unit-linked variable annuities | | (1 | ) | | | (0.02 | ) | | | (1 | ) | | | (0.01 | ) |

| Interest expense on uncertain tax positions | | 1 | | | | 0.02 | | | | — | | | | — | |

| Other (1) | | 1 | | | | 0.02 | | | | 25 | | | | 0.37 | |

| Uncertain tax positions and other tax related items | | 12 | | | | 0.18 | | | | 75 | | | | 1.12 | |

| Net income attributable to noncontrolling interest | | 4 | | | | 0.06 | | | | 5 | | | | 0.07 | |

| Adjusted operating income | | 1,606 | | | | 24.34 | | | | 1,003 | | | | 15.04 | |

| Less notable items | | — | | | | — | | | | (114 | ) | | | (1.71 | ) |

| Adjusted operating income, excluding notable items | $ | 1,606 | | | $ | 24.34 | | | $ | 1,117 | | | $ | 16.75 | |

| (1) | The Other line item includes pension risk transfer day one loss, market value adjustments on surrender charges and other immaterial items. |

| REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES Reconciliation of Consolidated Effective Income Tax Rates (Dollars in millions) |

| | | | |

| (Unaudited) | Three Months Ended September 30, 2026 | | Nine Months Ended September 30, 2026 |

| | Pre-tax Income (Loss) | | Income Taxes | | Effective Tax Rate (1) | | Pre-tax Income (Loss) | | Income Taxes | | Effective Tax Rate (1) |

| GAAP income | $ | 624 | | | $ | 167 | | | 26.8 | % | | $ | 1,670 | | | $ | 418 | | | 25.1 | % |

| Reconciliation to adjusted operating income: | | | | | | | | | | | |

| Realized and unrealized (gains) losses, derivatives and other, included in investment related gains (losses), net | | 222 | | | | 50 | | | | | | 601 | | | | 131 | | | |

| Market risk benefits remeasurement (gains) losses | | (26 | ) | | | (5 | ) | | | | | (30 | ) | | | (6 | ) | | |

| Realized (gains) losses on funds withheld, included in investment income, net of related expenses | | (1 | ) | | | — | | | | | | 5 | | | | 1 | | | |

| Embedded derivatives: | | | | | | | | | | | |

| Included in investment related gains/losses, net | | (104 | ) | | | (22 | ) | | | | | (147 | ) | | | (31 | ) | | |

| Included in interest credited | | 4 | | | | — | | | | | | 7 | | | | 1 | | | |

| Investment (income) loss on unit-linked variable annuities | | — | | | | — | | | | | | 1 | | | | — | | | |

| Interest credited on unit-linked variable annuities | | — | | | | — | | | | | | (1 | ) | | | — | | | |

| Interest expense on uncertain tax positions | | — | | | | — | | | | | | 1 | | | | — | | | |

| Other (2) | | 17 | | | | 3 | | | | | | 1 | | | | — | | | |

| Uncertain tax positions and other tax related items | | — | | | | (15 | ) | | | | | — | | | | (12 | ) | | |

| Adjusted operating income | | 736 | | | | 178 | | | 24.1 | % | | | 2,108 | | | | 502 | | | 23.8 | % |

| Less notable items | | — | | | | — | | | | | | — | | | | — | | | |

| Adjusted operating income, excluding notable items | $ | 736 | | | $ | 178 | | | | | $ | 2,108 | | | $ | 502 | | | |

| (1) | The Company rounds amounts in the financial statements to millions and calculates the effective tax rate from the underlying whole-dollar amounts. Thus certain amounts may not recalculate based on the numbers due to rounding. |

| (2) | The Other line item includes pension risk transfer day one loss, market value adjustments on surrender charges and other immaterial items. |

| REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES Reconciliation of Consolidated Income before Income Taxes to Pre-tax Adjusted Operating Income (Dollars in millions) |

| | | | |

| (Unaudited) | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Income before income taxes | $ | 624 | | | $ | 320 | | | $ | 1,670 | | | $ | 1,030 | |

| Reconciliation to pre-tax adjusted operating income: | | | | | | | |

| Realized (gains) losses, derivatives and other, included in investment related gains (losses), net | | 222 | | | | (1 | ) | | | 601 | | | | 147 | |

| Market risk benefits remeasurement (gains) losses | | (26 | ) | | | (1 | ) | | | (30 | ) | | | 11 | |

| Realized (gains) losses on funds withheld, included in investment income, net of related expenses | | (1 | ) | | | 19 | | | | 5 | | | | 17 | |

| Embedded derivatives: | | | | | | | |

| Included in investment related gains/losses, net | | (104 | ) | | | 33 | | | | (147 | ) | | | 41 | |

| Included in interest credited | | 4 | | | | 1 | | | | 7 | | | | 13 | |

| Investment (income) loss on unit-linked variable annuities | | — | | | | 1 | | | | 1 | | | | 1 | |

| Interest credited on unit-linked variable annuities | | — | | | | (1 | ) | | | (1 | ) | | | (1 | ) |

| Interest expense on uncertain tax positions | | — | | | | — | | | | 1 | | | | — | |

| Other (1) | | 17 | | | | 14 | | | | 1 | | | | 32 | |

| Pre-tax adjusted operating income | | 736 | | | | 385 | | | | 2,108 | | | | 1,291 | |

| Less notable items | | — | | | | (149 | ) | | | — | | | | (149 | ) |

| Pre-tax adjusted operating income, excluding notable items | $ | 736 | | | $ | 534 | | | $ | 2,108 | | | $ | 1,440 | |

| (1) | The Other line item includes pension risk transfer day one loss, market value adjustments on surrender charges and other immaterial items. |

| REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES Per Share and Shares Data (In thousands, except per share data) |

| | | | |

| (Unaudited) | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Earnings per share from net income (loss): | | | | | | | |

| Basic earnings per share | $ | 6.98 | | | $ | 3.85 | | | $ | 19.09 | | | $ | 10.89 | |

| Diluted earnings per share | $ | 6.92 | | | $ | 3.81 | | | $ | 18.91 | | | $ | 10.78 | |

| | | | | | | | |

| Diluted earnings per share from adjusted operating income | $ | 8.49 | | | $ | 4.66 | | | $ | 24.34 | | | $ | 15.04 | |

| Weighted average number of common and common equivalent shares outstanding | | 65,774 | | | | 66,508 | | | | 65,973 | | | | 66,694 | |

| (Unaudited) | At September 30, |

| | | 2026 | | | | 2025 | |

| Treasury shares | | 20,268 | | | | 19,602 | |

| Common shares outstanding | | 65,043 | | | | 65,709 | |

| Book value per share outstanding | $ | 178.89 | | | $ | 197.52 | |

| Book value per share outstanding, before impact of AOCI | $ | 179.51 | | | $ | 158.67 | |

| Reconciliation of Book Value Per Share to Book Value Per Share Excluding AOCI and B36 Derivatives |

| | |

| (Unaudited) | At September 30, |

| | | 2026 | | | | 2025 | |

| Book value per share outstanding | $ | 178.89 | | | $ | 197.52 | |

| Less effect of AOCI: | | | |

| Accumulated currency translation adjustment | | 1.83 | | | | 1.27 | |

| Unrealized (depreciation) appreciation of securities | | (169.13 | ) | | | (63.89 | ) |

| Effect of updating discount rates on future policy benefits | | 166.65 | | | | 101.69 | |

| Change in instrument-specific credit risk for market risk benefits | | 0.04 | | | | 0.01 | |

| Pension and postretirement benefits | | (0.01 | ) | | | (0.23 | ) |

| Book value per share outstanding, before impact of AOCI | | 179.51 | | | | 158.67 | |

| Less effect of B36 derivatives | | 0.92 | | | | (1.16 | ) |

| Book value per share outstanding, before impact of AOCI and B36 derivatives | $ | 178.59 | | | $ | 159.83 | |

| REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES Reconciliation of Shareholders’ Average Equity to Shareholders’ Average Equity Excluding AOCI (Dollars in millions) |

| | |

| (Unaudited) | |

| Trailing Twelve Months Ended September 30, 2026: | Average Equity |

| Shareholders' average equity | $ | 13,013 | |

| Less effect of AOCI: | |

| Accumulated currency translation adjustment | | 109 | |

| Unrealized (depreciation) appreciation of securities | | (6,513 | ) |

| Effect of updating discount rates on future policy benefits | | 8,380 | |

| Change in instrument-specific credit risk for market risk benefits | | 2 | |

| Pension and postretirement benefits | | (6 | ) |

| Shareholders' average equity, excluding AOCI | | 11,041 | |

| Year-to-date notable items, net of tax | | (46 | ) |

| Shareholders' average equity, excluding AOCI and notable items | $ | 11,087 | |

| Reconciliation of Trailing Twelve Months of Consolidated Net Income to Adjusted Operating Income and Related Return on Equity (Dollars in millions) |

| | | | |

| (Unaudited) | | | Return on Equity |

| Trailing Twelve Months Ended September 30, 2026: | Income | |

| Net income available to RGA shareholders | $ | 1,711 | | | | 13.1 | % |

| Reconciliation to adjusted operating income: | | | | | |

| Capital (gains) losses, derivatives and other, net | | 602 | | | |

| Change in fair value of embedded derivatives | | (129 | ) | | |

| Tax expense on uncertain tax positions and other tax related items | | (69 | ) | | |

| Net income attributable to noncontrolling interest | | 6 | | | |

| Adjusted operating income | | 2,121 | | | | 19.2 | % |

| Less notable items after tax | | — | | | |

| Adjusted operating income, excluding notable items | $ | 2,121 | | | | 19.1 | % |

| REINSURANCE GROUP OF AMERICA, INCORPORATED AND SUBSIDIARIES Condensed Consolidated Statements of Income (Dollars in millions) |

| | | | |

| (Unaudited) | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Revenues: | | | | | | | |

| Net premiums | $ | 5,352 | | | $ | 4,280 | | | $ | 14,419 | | | $ | 12,450 | |

| Investment income, net of related expenses | | 1,934 | | | | 1,475 | | | | 5,499 | | | | 4,115 | |

| Investment related gains (losses), net | | (85 | ) | | | 13 | | | | (331 | ) | | | (110 | ) |

| Other revenue | | 349 | | | | 436 | | | | 1,094 | | | | 608 | |

| Total revenues | | 7,550 | | | | 6,204 | | | | 20,681 | | | | 17,063 | |

| Benefits and expenses: | | | | | | | |

| Claims and other policy benefits | | 5,420 | | | | 4,356 | | | | 14,519 | | | | 12,223 | |

| Future policy benefits remeasurement (gains) losses | | (40 | ) | | | 85 | | | | (41 | ) | | | 97 | |

| Market risk benefits remeasurement (gains) losses | | (26 | ) | | | (1 | ) | | | (30 | ) | | | 11 | |

| Interest credited | | 533 | | | | 547 | | | | 1,630 | | | | 1,160 | |

| Policy acquisition costs and other insurance expenses | | 586 | | | | 471 | | | | 1,606 | | | | 1,321 | |

| Other operating expenses | | 357 | | | | 328 | | | | 1,031 | | | | 953 | |

| Interest expense | | 96 | | | | 98 | | | | 296 | | | | 268 | |

| Total benefits and expenses | | 6,926 | | | | 5,884 | | | | 19,011 | | | | 16,033 | |

| Income before income taxes | | 624 | | | | 320 | | | | 1,670 | | | | 1,030 | |

| Provision for income taxes | | 167 | | | | 65 | | | | 418 | | | | 306 | |

| Net income | | 457 | | | | 255 | | | | 1,252 | | | | 724 | |

| Net income attributable to noncontrolling interest | | 1 | | | | 2 | | | | 4 | | | | 5 | |

| Net income available to RGA shareholders | $ | 456 | | | $ | 253 | | | $ | 1,248 | | | $ | 719 | |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104697006/en/

Investor ContactCrystal Lu Senior Vice President - Investor Relations (636) 736-7000

Source: Reinsurance Group of America, Incorporated

Search Investors

Medical

  • Videos
  • November 2026
  • 1 minutes

Video: U.S. Cancer Trends in Transition

By

  • Kaitlyn Fleigle

Skip to Authors and Experts

In Brief

Cancer mortality in the U.S. has declined significantly over the past two decades. That's the good news. But the full story is far more complex, especially for younger adults.

Learn more by reading our article that expands on this topic, then contact RGA to discuss a partnership to put these insights into action. 

Meet the Authors & Experts

Kaitlyn Flegile Professional Headshot

Author

Kaitlyn Fleigle

Actuary, Strategic Research, Innovation & Content

Connect With Us

Curious? So are we. Let's connect and come up with better solutions together. 

linkedin icon      facebook icon

RGA Central

RGA Central is a convenient client portal that provides a single point of access to exclusive applications and insights.

Learn More

Contact Us

At RGA, we are eager to speak with clients and counterparties. Contact us to learn more about the resources, solutions, and services available.

Contact Us

               Red RGA Logo  

   

Trusted partner. Proven results.

 

Cookie Settings

Copyright © 2026 RGA Reinsurance Company. All Rights Reserved.

Medical

  • Articles
  • November 2026
  • 9 minutes

How Behavioral Science Can Improve CI Insurance Success

By

  • Peter Hovard
  • Lizzy Lubczanski

Skip to Authors and Experts

A smiling older couple of Asian descent sit in a field of white flowers

In Brief

Part 3 of this article series explores why the future success of CI products also depends on behavioral factors that influence consumer decisions, underwriting outcomes, and long-term engagement. Part 1  explored how medical science is reshaping the critical illness (CI) landscape. Part 2 focused on actuarial science – because even the most clinically sophisticated CI product will fail if it cannot remain affordable, sustainable, and fit for purpose over time.

Key takeaways

  • Behavioral biases can obscure consumers’ understanding of their need for CI protection, making effective risk communication as important as product design.
  • Simplifying complex products and decisions can improve understanding, trust, and customer engagement without sacrificing value.
  • Behavioral science can help insurers improve acquisition, underwriting, and long-term health outcomes by designing around how people actually think and act.

Critical illness (CI) remains a cornerstone protection product across many Asia Pacific (APAC) markets. Yet persistent underinsurance highlights a central challenge: Even where awareness is high, many consumers remain unprotected or under-protected.  

In Hong Kong, for example, one estimate suggests six in 10 people lack CI coverage.1 In Singapore, one of Asia's most developed insurance markets, a 2022 protection gap study found that nearly three-quarters of critical illness protection needs remain unmet, highlighting the persistence of underinsurance even where awareness and insurance penetration are relatively high.2 

This gap is not solely a function of price, product availability, or distribution. It reflects something more fundamental: CI can be designed more effectively around how humans actually think and behave. 

Behavioral science helps close the gap. It sheds light on how people perceive risk, process complexity, and make decisions about uncertain future events. As CI evolves alongside advances in medicine – toward longer treatment journeys and more chronic conditions – embedding behavioral insights across the customer journey has become critical to success. 

Complexity reduces understanding, trust, and conversion 

Even when consumers acknowledge their need for protection, they face a second barrier: complexity. CI products have grown more sophisticated, adding layers such as multiple conditions, severity tiers, and benefit structures. While technically valuable, this can overwhelm buyers. 

This link between complexity and engagement is echoed in RGA’s recent research on senior insurance consumers across Asia, which found that many older adults struggle to access products that meet their needs because offerings are difficult to understand.  

For example, Chinese respondents reported that difficulty understanding policies is their top barrier to pursuing three types of insurance: life, private health, CI. Apart from premium cost, Taiwanese seniors said complex and confusing policy language is their top barrier to purchasing CI, life, or private health insurance. 

RGA’s research on the needs and experiences of senior consumers aligns with a broader body of behavioral economics research on consumer decision-making. Complexity introduces decision friction, which may reduce conversion rates.

When customers struggle to understand a product’s purpose or how it works, they are more likely to not engage, postpone their research or abandon the purchase entirely. Research across financial products shows that when decision-making becomes too complex, participation drops significantly unless the process is simplified. 

For example, a National Bureau of Economic Research (NBER) study found that simplifying a complex retirement savings decision by offering employees a single, pre-selected enrollment option dramatically increased participation. In one company, this "Quick Enrollment" approach tripled 401(k) enrollment among new hires, while similar simplification efforts increased participation among existing nonparticipants by 10 to 20 percentage points, demonstrating how reducing cognitive burden can translate directly into higher action rates.3 

In a black and white image, an older couple flies a bright red kite

RGA's Biometric Insights

Not every breakthrough moves mortality. We assess each emerging driver by magnitude, timing, and probability, and recommend changes to assumptions only where the evidence supports them.

Explore biometric insights

Making risk easier to understand 

Complexity does not arise only from product design. Consumers may also find the underlying risk difficult to interpret, particularly when assessing an uncertain event that could occur years in the future. 

People often underestimate their personal likelihood of experiencing adverse health events, a tendency known as optimism bias. Research also suggests that comparative optimism, the belief that others are more likely to experience harm, can be associated with lower adoption of protective behaviors.4 When consumers view serious illness as distant or unlikely to affect them personally, they may postpone protection decisions or disengage from them altogether. 

Traditional risk communication can add to this difficulty. Incidence rates, probabilities, and other statistics may be hard to translate into a personally meaningful understanding of risk, particularly when they require consumers to interpret small probabilities, ratios, or proportions. For CI, the challenge is not simply to communicate the likelihood of diagnosis, but to help customers understand what serious illness could mean for their finances, family, recovery, and ability to earn an income. 

Insurers can simplify this decision by making risk more concrete and personally relevant. Rather than relying only on incidence statistics, communications can use relatable scenarios that link protection to consumers’ personal needs in vivid ways. Real-world examples illustrate the potential financial consequences of diagnosis, treatment, recovery, and longer-term survival. The objective is not to heighten fear, but to help customers form a clearer and more useful understanding of the risk so they can evaluate their need for protection with confidence.

Simplifying the decision unlocks demand 

Behavioral insights consistently show that simplifying choices increases participation. For example, the same NBER report found that separating a complex retirement decision into simpler components can increase participation by reducing the number of choices consumers must evaluate at once. CI faces a similar issue: Customers are often asked to make multiple decisions simultaneously – coverage levels, product structures, optional features – before they fully understand whether the product meets their needs.  

Yet simplification does not necessarily mean removing product features or reducing customer choice. As behavioral science research has shown, many insurance products contain inherent complexity that is essential to delivering value; the challenge is making that complexity easier to navigate and understand.  

As RGA's behavioral science research suggests , the goal is to bring order to complexity through practical design and communication techniques, including: 

  • Breaking complex decisions into smaller, more manageable steps 
  • Presenting information progressively rather than all at once 
  • Using intuitive explanations and relatable examples 
  • Highlighting the most relevant information at key decision points 

Simplified customer journeys, combined with clearer explanations, can help re-energize demand by making CI products more accessible and easier to understand. especially relevant in digital channels, opportunities to explain complex features are limited.

Strategies to simplify underwriting and improve accuracy 

Behavioral science suggests that underwriting can be simplified without reducing its rigor. The goal is not necessarily to ask fewer questions, but to make the disclosure process easier for customers to understand and complete accurately. 

Traditional underwriting relies heavily on self-disclosure, yet responses are often inaccurate due to misunderstanding, ambiguity, or self-perception biases. For example, someone who smokes only occasionally may not identify as a "smoker," leading to underreporting. These disclosure gaps can affect both pricing accuracy and portfolio performance. 

Research from RGA's Behavioral Science team shows that thoughtfully designed forms can improve both customer experience and disclosure quality. In one RGA study, more structured, checklist-based questions were perceived as quicker and easier to complete than simpler free-text questions, even though they actually took slightly longer. Participants were also less likely to omit information and provided more complete disclosures, demonstrating that how questions are presented can matter more than the number of questions asked. 

Rather than removing underwriting complexity, these approaches help bring order to it, making the process feel simpler for customers while generating more accurate information for insurers. 

A woman reads from a red book with an older woman

Older-Age Underwriting: Rethinking mortality risk

As longevity reshapes insurance markets, underwriting for older applicants must move beyond standard age-based assumptions to account for later-life indicators.

Read the research

Beyond purchase: Supporting health behaviors over time 

Many conditions covered by CI have strong behavioral drivers, including lifestyle choices, preventive care, treatment adherence, and ongoing disease management. As CI products expand beyond financial protection to support prevention, recovery, and long-term health management, insurers will need to recognize a fundamental challenge: managing health behaviors is difficult. 

This becomes particularly relevant as insurers explore their role in areas such as chronic disease management and medication adherence.

For example, adherence remains a well-documented challenge across many treatments, including newer therapies such as GLP-1 medications.

Whether delivered through human coaching, adviser engagement, or digital health programs, behavioral interventions can help individuals stay engaged with treatment plans, leading to better health outcomes for customers and potentially improved risk outcomes for insurers.   

If CI products take on a role in supporting disease prevention through promoting healthy lifestyles, insurers will need to apply behavioral science to understand and influence health behaviors. Behavioral science shows that sustained behavior changes rarely occur through information alone. Successful programs typically combine behavioral design techniques such as: 

  • Clear goal setting 
  • Timely reminders 
  • Simplified routines 
  • Feedback loops Incentives 
  • Social support

These approaches help people maintain desired behaviors long after their initial motivation fades. 

Programs that incorporate these evidence-based behavioral principles are more likely to generate meaningful and lasting impact. Without them, initiatives may achieve strong initial enrollment but struggle to sustain engagement over time. 

An important consideration is that participation in health programs often reflects self-selection. Individuals who choose to engage are frequently already more proactive about their health than the broader population. While these programs can still create significant value, understanding this dynamic is essential when measuring outcomes, identifying who benefits most, and designing interventions capable of reaching less-engaged populations. 

The path forward: Simplifying CI for a more complex world 

Advances in medical science are making critical illness products more sophisticated, expanding coverage, improving treatment pathways, and creating new opportunities to support customers throughout their health journeys. Yet as products become more capable, they also risk becoming harder for customers to understand, buy, and use. 

The challenge for insurers is therefore not necessarily to remove complexity, but to bring order to it. RGA's behavioral science research shows that people engage more effectively when decisions are structured intuitively, information is presented clearly, and complex tasks are broken into manageable steps. These principles can help insurers preserve the value of modern CI products while making them easier for customers to navigate. 

This need for simplification extends across the entire customer journey: 

Customer acquisition:

Helping consumers understand evolving financial and health risks, recognize protection needs, and navigate product choices with confidence. 

Underwriting:

Improving disclosure quality and risk assessment through clearer questions, better sequencing, and more customer-friendly application experiences. 

Health behavior management:

Supporting sustained engagement with prevention, treatment, and disease-management programs through evidence-based behavioral strategies. 

Ultimately, the future success of CI may depend not only on advances in medicine, underwriting, or product design, but on insurers' ability to make those advances accessible to the people they are intended to serve. The next generation of CI products will succeed when they combine sophisticated protection with simple, intuitive customer experiences that reflect how people actually think, decide, and behave. 

Read Part 1 of this series, which examines how medical science is reshaping the CI landscape, and Part 2 , which addresses how CI products will fail if they cannot remain affordable, sustainable, and fit for purpose over time. 


Redesigning CI is not a theoretical exercise – it is a strategic imperative. If you are exploring how to future‑proof your CI portfolio in Asia Pacific, now is the time to start the conversation. Contact us to discuss how actuarial, medical, and behavioral insights can come together to support your CI redesign journey, from near-term optimization to longer-term transformation.

More Like This...

Meet the Authors & Experts

Peter Hovard

Author

Peter Hovard

Vice President and Chief Behavioral Scientist

Lizzy Lubczanski

Author

Lizzy Lubczanski

Lead Behavioral Scientist

References

1 https://insuranceasia.com/insurance/news/six-in-10-in-hk-without-critical-illness-insurance   
2 https://www.lia.org.sg/media/3972/lia-pgs-2022-press-release_final_8-sep-2023.pdf   
3 https://www.nber.org/papers/w11979    
4 Kathleen McColl et al., “Are People Optimistically Biased about the Risk of COVID-19 Infection? Lessons from the First Wave of the Pandemic in Europe,” International Journal of Environmental Research and Public Health 19, no. 1 (2022): 436, view the study .  

Connect With Us

Curious? So are we. Let's connect and come up with better solutions together. 

linkedin icon      facebook icon

RGA Central

RGA Central is a convenient client portal that provides a single point of access to exclusive applications and insights.

Learn More

Contact Us

At RGA, we are eager to speak with clients and counterparties. Contact us to learn more about the resources, solutions, and services available.

Contact Us

               Red RGA Logo  

   

Trusted partner. Proven results.

 

Cookie Settings

Copyright © 2026 RGA Reinsurance Company. All Rights Reserved.

Prompts

Reinsurance Group of America, Incorporated (ticker RGA), listed in United States.

Company History

Date Change Detail
— Former tickers RZB

ETFs Holding Reinsurance Group of America, Incorporated

ETF Weight in ETF Shares Market value As of
EPSB 2.90% 783 $ 215.442K Nov 13, 2026
GLRY 2.79% 18,700 $ 4.601M Aug 31, 2026
EPSV 2.70% 579 $ 159.312K Nov 13, 2026
EPMB 2.50% 418 $ 115.013K Nov 13, 2026
RGEF 2.39% 68,375 $ 18.521M Nov 17, 2026
OASC 2.31% 8,827 $ 2.172M Aug 31, 2026
EPMV 2.20% 372 $ 102.356K Nov 13, 2026
FLV 1.53% 23,712 $ 5.834M Aug 31, 2026
KDVD 1.44% 570 $ 121.211K Jun 30, 2026
FTKI 1.12% 1,050 $ 285.453K Nov 16, 2026
ROE 1.10% 10,106 $ 2.71M Nov 18, 2026
SDVD 1.09% 36,482 $ 9.971M Nov 11, 2026
VAMO 0.97% 4,458 $ 1.056M Jul 31, 2026
SEIV 0.97% 66,922 $ 14.231M Jun 30, 2026
AIVL 0.86% 16,762 $ 3.564M Jun 30, 2026
FFSM 0.71% 44,856 $ 10.624M Jul 31, 2026
SMDX 0.51% 2,374 $ 643.069K Nov 17, 2026
LOWV 0.51% 4,213 $ 1.037M Aug 31, 2026
AVMV 0.45% 13,695 $ 3.71M Nov 16, 2026
ABCS 0.44% 224 $ 55.113K Aug 31, 2026
JMEE 0.41% 43,564 $ 11.688M Nov 17, 2026
CLSE 0.40% 14,741 $ 3.627M Aug 31, 2026
DFAT 0.40% 457,238 $ 125.164M Nov 12, 2026
JSTC 0.38% 4,120 $ 1.116M Nov 17, 2026
GVLU 0.33% 3,170 $ 858.69K Nov 17, 2026
HSMV 0.32% 64 $ 17.399K Nov 16, 2026
REMC 0.31% 49 $ 10.42K Jun 30, 2026
JHPI 0.25% 20,396 $ 522.953K Jun 30, 2026
AVMC 0.22% 4,448 $ 1.205M Nov 16, 2026
ENHU 0.20% 68 $ 18.486K Nov 16, 2026
AVIE 0.19% 114 $ 30.88K Nov 16, 2026
VFVA 0.19% 7,216 $ 1.775M Aug 31, 2026
RUSC 0.18% 660 $ 140.349K Jun 30, 2026
INRO 0.12% 2,549 $ 692.971K Nov 16, 2026
AVSU 0.11% 1,923 $ 520.902K Nov 16, 2026
DFSU 0.11% 9,492 $ 2.598M Nov 12, 2026
MSSM 0.07% 2,029 $ 499.215K Aug 31, 2026
AVLC 0.07% 3,895 $ 1.055M Nov 16, 2026
DFUV 0.06% 36,916 $ 10.105M Nov 12, 2026
EBI 0.06% 1,757 $ 432.292K Aug 31, 2026
AVUS 0.06% 32,551 $ 8.817M Nov 16, 2026
DFAC 0.06% 181,088 $ 49.571M Nov 12, 2026
DXUV 0.05% 12,469 $ 3.413M Nov 12, 2026
LCTU 0.05% 2,107 $ 572.809K Nov 16, 2026
DCOR 0.05% 79,646 $ 21.802M Nov 12, 2026
DFAU 0.03% 15,937 $ 4.363M Nov 12, 2026
DFUS 0.03% 20,809 $ 5.696M Nov 12, 2026
FMDE 0.03% 8,759 $ 1.863M Jun 30, 2026
SYZ 0.02% 80 $ 17.012K Jun 30, 2026
MSLC 0.02% 2,520 $ 620.021K Aug 31, 2026
DFSV 0.01% 8,541 $ 2.338M Nov 12, 2026
DFLV 0.01% 1,680 $ 459.883K Nov 12, 2026
DFAS 0.00% 624 $ 170.814K Nov 12, 2026
IALT short 0.00% -132 $ -35.886K Nov 16, 2026
NTRL 0.00% 827 $ 0.00 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
RGA canonical Common share — US nyse 271.53 USD 2026-11-10
RZC Bond — US nyse — —